Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Adma Biologics (ADMA) over the last 14 years, with Q3 2025 value amounting to $28.8 million.

  • Adma Biologics' Accumulated Expenses rose 469.22% to $28.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.8 million, marking a year-over-year increase of 469.22%. This contributed to the annual value of $34.1 million for FY2024, which is 360.28% up from last year.
  • As of Q3 2025, Adma Biologics' Accumulated Expenses stood at $28.8 million, which was up 469.22% from $43.9 million recorded in Q2 2025.
  • Adma Biologics' 5-year Accumulated Expenses high stood at $43.9 million for Q2 2025, and its period low was $8.6 million during Q1 2021.
  • Over the past 5 years, Adma Biologics' median Accumulated Expenses value was $27.5 million (recorded in 2024), while the average stood at $24.7 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 10579.43% in 2021, then crashed by 779.78% in 2024.
  • Quarter analysis of 5 years shows Adma Biologics' Accumulated Expenses stood at $17.2 million in 2021, then surged by 45.16% to $25.0 million in 2022, then surged by 31.73% to $32.9 million in 2023, then grew by 3.6% to $34.1 million in 2024, then fell by 15.48% to $28.8 million in 2025.
  • Its Accumulated Expenses stands at $28.8 million for Q3 2025, versus $43.9 million for Q2 2025 and $31.6 million for Q1 2025.